64 related articles for article (PubMed ID: 28832961)
1. Risk of death from breast cancer after treatment for ductal carcinoma in situ.
Wadsten C; Garmo H; Fredriksson I; Sund M; Wärnberg F
Br J Surg; 2017 Oct; 104(11):1506-1513. PubMed ID: 28832961
[TBL] [Abstract][Full Text] [Related]
2. Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study.
Mannu GS; Wang Z; Broggio J; Charman J; Cheung S; Kearins O; Dodwell D; Darby SC
BMJ; 2020 May; 369():m1570. PubMed ID: 32461218
[TBL] [Abstract][Full Text] [Related]
3. Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case-control study.
Rask G; Wadsten C; Acs B; Hartman J; Fredriksson I; Garmo H; Wärnberg F; Sund M
Br J Surg; 2024 Jan; 111(2):. PubMed ID: 38395442
[TBL] [Abstract][Full Text] [Related]
4. Health-related behaviors and mortality outcomes in women diagnosed with ductal carcinoma in situ.
Veal CT; Hart V; Lakoski SG; Hampton JM; Gangnon RE; Newcomb PA; Higgins ST; Trentham-Dietz A; Sprague BL
J Cancer Surviv; 2017 Jun; 11(3):320-328. PubMed ID: 28058695
[TBL] [Abstract][Full Text] [Related]
5. Reassessing treatment strategies for DCIS: analysis of survival and recurrence patterns.
Mokbel K; Alamoodi M
Breast Cancer Res Treat; 2024 Jun; 205(2):423-424. PubMed ID: 38361145
[No Abstract] [Full Text] [Related]
6. Adjuvant radiotherapy versus observation following lumpectomy in ductal carcinoma in-situ: A meta-analysis of randomized controlled trials.
Garg PK; Jakhetiya A; Pandey R; Chishi N; Pandey D
Breast J; 2018 May; 24(3):233-239. PubMed ID: 28833776
[TBL] [Abstract][Full Text] [Related]
7. Best practices for multidisciplinary integration of a DCIS genomic assay into clinical practice.
Alvarado M; Lucci A; Manders J
J Surg Oncol; 2017 Dec; 116(8):1016-1020. PubMed ID: 28833159
[TBL] [Abstract][Full Text] [Related]
8. Radiation Therapy Following Breast Conserving Surgery for Ductal Carcinoma in situ: Yes or No?
Stoleru LS; Stoleru S
Chirurgia (Bucur); 2017; 112(4):403-412. PubMed ID: 28862116
[TBL] [Abstract][Full Text] [Related]
9. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
Curigliano G; Burstein HJ; Winer EP; Gnant M; Dubsky P; Loibl S; Colleoni M; Regan MM; Piccart-Gebhart M; Senn HJ; Thürlimann B; ; André F; Baselga J; Bergh J; Bonnefoi H; Brucker SY; Cardoso F; Carey L; Ciruelos E; Cuzick J; Denkert C; Di Leo A; Ejlertsen B; Francis P; Galimberti V; Garber J; Gulluoglu B; Goodwin P; Harbeck N; Hayes DF; Huang CS; Huober J; Hussein K; Jassem J; Jiang Z; Karlsson P; Morrow M; Orecchia R; Osborne KC; Pagani O; Partridge AH; Pritchard K; Ro J; Rutgers EJT; Sedlmayer F; Semiglazov V; Shao Z; Smith I; Toi M; Tutt A; Viale G; Watanabe T; Whelan TJ; Xu B
Ann Oncol; 2017 Aug; 28(8):1700-1712. PubMed ID: 28838210
[TBL] [Abstract][Full Text] [Related]
10. Carcinoma in situ of the breast in New South Wales, Australia: Current status and trends over the last 40 year.
Jacklyn G; Morrell S; McGeechan K; Houssami N; Irwig L; Pathmanathan N; Barratt A
Breast; 2018 Feb; 37():170-178. PubMed ID: 28882419
[TBL] [Abstract][Full Text] [Related]
11. Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials.
Gyawali B; Niraula S
Cancer Treat Rev; 2017 Nov; 60():18-23. PubMed ID: 28863313
[TBL] [Abstract][Full Text] [Related]
12. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Blok EJ; Kroep JR; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Putter H; van den Bosch J; Maartense E; van Leeuwen-Stok AE; Liefers GJ; Nortier JWR; Rutgers EJT; van de Velde CJH;
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922787
[TBL] [Abstract][Full Text] [Related]
13. Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma
Sagara Y; Julia W; Golshan M; Toi M
Front Oncol; 2017; 7():192. PubMed ID: 28894698
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ.
Bosch DE; Kilgore MR; Schmidt RA; Swanson PE; Rendi MH; Chang OH
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):543-547. PubMed ID: 28885232
[TBL] [Abstract][Full Text] [Related]
15. Current margin practice and effect on re-excision rates following the publication of the SSO-ASTRO consensus and ABS consensus guidelines: a national prospective study of 2858 women undergoing breast-conserving therapy in the UK and Ireland.
Tang SS; Kaptanis S; Haddow JB; Mondani G; Elsberger B; Tasoulis MK; Obondo C; Johns N; Ismail W; Syed A; Kissias P; Venn M; Sundaramoorthy S; Irwin G; Sami AS; Elfadl D; Baggaley A; Remoundos DD; Langlands F; Charalampoudis P; Barber Z; Hamilton-Burke WLS; Khan A; Sirianni C; Merker LAG; Saha S; Lane RA; Chopra S; Dupré S; Manning AT; St John ER; Musbahi A; Dlamini N; McArdle CL; Wright C; Murphy JO; Aggarwal R; Dordea M; Bosch K; Egbeare D; Osman H; Tayeh S; Razi F; Iqbal J; Ledwidge SFC; Albert V; Masannat Y
Eur J Cancer; 2017 Oct; 84():315-324. PubMed ID: 28865259
[TBL] [Abstract][Full Text] [Related]
16. Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma.
Chen Z; Yang J; Li S; Lv M; Shen Y; Wang B; Li P; Yi M; Zhao X; Zhang L; Wang L; Yang J
PLoS One; 2017; 12(9):e0182397. PubMed ID: 28863134
[TBL] [Abstract][Full Text] [Related]
17. Chronic pain and other symptoms among breast cancer survivors: prevalence, predictors, and effects on quality of life.
Hamood R; Hamood H; Merhasin I; Keinan-Boker L
Breast Cancer Res Treat; 2018 Jan; 167(1):157-169. PubMed ID: 28861642
[TBL] [Abstract][Full Text] [Related]
18. African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages.
Arciero CA; Yang J; Peng L; Ward KC; O'Regan R; Sahin AA; Li X
Breast Cancer Res Treat; 2017 Dec; 166(3):743-755. PubMed ID: 28856481
[TBL] [Abstract][Full Text] [Related]
19. MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.
Bösl A; Spitzmüller A; Jasarevic Z; Rauch S; Jäger S; Offner F
PLoS One; 2017; 12(8):e0183458. PubMed ID: 28850621
[TBL] [Abstract][Full Text] [Related]
20. Core-needle biopsy of breast cancer is associated with a higher rate of distant metastases 5 to 15 years after diagnosis than FNA biopsy.
Sennerstam RB; Franzén BSH; Wiksell HOT; Auer GU
Cancer Cytopathol; 2017 Oct; 125(10):748-756. PubMed ID: 28837268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
